Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Bipolar Disorder Landscape Report with DLI's Clinical Trial Assessment, Product Portfolio Extension, and Post Launch Services | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

09 Oct, 2023, 14:01 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 9, 2023 /PRNewswire/ -- Bipolar Disorder is a commonly occurring mental illness which has taken over the world in storm. According to an epidemiology study conducted by the NIH, an estimated 2.9% of adolescents are living with bipolar disorder, and 2.6% had severe impairment. This alarmingly increased disease burden is raising mental health cognizance among the masses to a large extent.

Bipolar disorder is a mental health condition that causes extreme and fluctuating mood swings. These mood swings typically include episodes of mania or hypomania and periods of depression. It can have a significant impact on a person's daily life, relationships, and overall well-being.  Bipolar disorder in children is also a common phenomenon and it indicates that mental well is not only important for adults but children must also be shielded against mental health issues. Continuous R&D activities are going on to develop ideal bipolar disorder support options to the patients and risk groups.

Healthcare consulting services provided by DiseaseLandscape Insights are being obtained by the industry participants from across the globe. From treatment gaps identification, drug development, clinical trial feasibility analysis, and product pipeline assessment to price and market access, regulatory consulting, and commercial strategy analysis plans, DLI has been empowering them with the much-needed assistance. They are also leveraging DLI's market intelligence repository that can aid in the formulation of ideal pricing and reimbursement strategies.

Price and Market Access

Shedding Light on The Causes and Symptoms of This Ailment:

The accurate causes behind the occurrence of this mental illness are not yet known. Many bipolar disorder books and research documents have stated that genetic issues, and imbalances in certain neurotransmitters, such as dopamine, serotonin, and norepinephrine may trigger this ailment. Some bipolar disorder online courses designed by health experts suggest that abnormalities in brain structure or function along with stressful life events, trauma, and significant life changes can also lead to the onset of this dreadful condition.

Coping with bipolar disorder is not an easy task due to the severity of its symptoms. Maniac episodes, hypomanic episodes, cycling pattern of mood episodes, and depressive episodes result from bipolar disorder. It may trigger suicidal thoughts or make a person extremely aggressive. Bipolar disorder and relationships is a much talked about topic. Several bipolar disorder research statistics have revealed that people with this ailment eventually end up having issues in their personal and professional relationships.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Bipolar Disorder @

https://www.diseaselandscape.com/requestsample/postid/41

Diagnosis and Treatment:

Bipolar disorder diagnosis can be quite complexed. It includes a series of physical, mental, and biological examinations. Mood assessment, clinical evaluation, blood tests, imaging tests, and physiological assessments are generally conducted before coming to a definite conclusion.

There is no permanent cure for this ailment. But with advancements in the medical sector numerous bipolar disorder treatment centers have emerged over time. Bipolar disorder therapy options in the form of cognitive-behavioral therapy (CBT), dialectical-behavior therapy (DBT), and interpersonal therapy (IPT), can be beneficial are recommended to the patients. Apart from that bipolar disorder medications like mood stabilizers, antidepressants, antianxiety medications, and adjunctive medications are administered to alleviate the symptoms.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

https://www.diseaselandscape.com/checkout?report_id=41

Final Words:

The mental health menace known as bipolar disorder is affecting a large part of the world's population. Individuals across any age or gender may be a victim of this ailment. People with this disorder face symptoms like anxiety, depression, suicidal thoughts, and extreme maniac episodes. It also takes a toll on the physical health. With growing cognizance about the importance of mental health, continuous research activities are being conducted to aid the efficient management of diseases like bipolar disorder. DLI has been actively participating in the R&D endeavours by providing the much-required pharma consulting services to the players.

Browse Through More Mental Health Disorders Research Reports

Related Reports:

Solid Tumor Diseases: A Comprehensive Guide to Detection and Therapeutic Strategies

Demodex Blepharitis: Diagnosis, Treatment, and Prevention

Duchenne Muscular Dystrophy (DMD): A Comprehensive Guide for Patients and Families

Hemophilia Disease Explained: Causes, Symptoms, and Treatment Options

Spinal Muscular Atrophy (SMA) Disease Chronicles: Navigating Life with Spinal Muscular Atrophy

Predictive analytics powered by AI: Unlocking Insights for the Future of Healthcare.

Natural Language Processing (NLP) in Healthcare: Unlocking the Potential.

Posluma: A Targeted Oncology Cutting-Edge Advancement in Prostate Cancer Imaging.

Fezolinetant by Veozah: Advancing Women's Health by Astellas Pharma Inc.

A Glimmer of Hope for Migraine Sufferers: Zavzpret.

Rethinking Treatment Options for a Better Future with Hemophilia Gene Therapy.

Reach New Heights with Mass Production of Benzathine Penicillin G as We Overcome the Challenge.

Case study on the development of novel medications.

Case Study: Software Application for Personalized Care with Data-Driven Insights.

Case Study: Cancer Vaccine Targeting an Antigen.

Case Study: Lung Cancer Immunotherapy Combination Trials.

Software implementation for inventory and supply chain management.

Asset scouting for cystic fibrosis.

The Successful Commercialization of a Revolutionary Non-Invasive Glucose Monitoring Device after Regulatory Approval.

Investing in pancreatic cancer chemotherapy drugs.

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  

Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com
Sales: +44-2038074155 
Asia Office: +917447409162
Blog: https://www.diseaselandscape.com/blogs 
Case Study: https://www.diseaselandscape.com/casestudies  
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.